Summary Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown significant anti-tumour effects in animal models. We performed a phase II study in previously untreated patients with advanced colorectal cancer, using a schedule of i.v. bolus infusions of 900 Mg m 2 once every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients. Toxicity mainly consisted of a highly selective neutropenia, which warrants further investigation of this agent in combination with myeloid growth factors.
Tallimustine is a synthetic derivative of the antiviral distamycin A, in which a formyl group at the N-terminal position has been replaced by an alkylating benzoyl mustard moiety (Arcamone et al., 1989) . Although its mechanism of action is not precisely known, its anti-tumour activity has been attributed to a very limited number of highly sequencespecific alkylations of DNA (Broggini et al., 1995) . Tallimustine binds preferentially to adenine-thymine rich sequences in the minor groove of DNA, inhibits the binding of transcription factors that recognise these sequences and specifically inhibits DNA ligase. Unlike classic alkylating agents it does not alkylate guanine N7 but only adenine N3 (Broggini et al., 1991; Coley et al., 1993 , Montecucco et al., 1991 . Furthermore, it has immunomodulating properties in that it augments T-cell-dependent antibody production (Riganti et al., 1992) . It displays potent anti-tumour effects on human and murine tumour cell lines as well as on murine transplated solid tumours and human tumour xenografts (Arcamone et al., 1989; Giuliani et al., 1988; Pezzoni et al., 1991) . Tallimustine is cross-resistant with doxorubicin but not with melphalan and cisplatin, and drug resistance is only partially mediated through mdr-J-p170 (Pezzoni et al., 1991; Geroni et al., 1993; Capolongo et al., 1993) . The doselimiting toxicity in phase I studies was a highly selective neutropenia (Sessa et al., 1994; Abigerges et al., 1993; Hageboutros et al., 1994 admissions for treatment with i.v. antibiotics. Grade IV neutropenia occurred between days 13 and 17 after the start of treatment and had a median duration of 4 (range 2-9) days. Of the 14 patients who received at least two cycles, toxicity-related dose reductions and treatment delays were performed in one (7%) and two (14%) patients respectively. In these 14 patients no cumulative effect on bone marrow toxicity was seen. Platelet toxicity occurred in only one patient (grade 2). One patient developed symptoms of arterial insufficiency of the left leg together with hypotension and anuria 13 days after the second administration of tallimustine. He also had afebrile grade IV neutropenia, which lasted only 2 days. Despite vigourous treatment with anticoagulants, pressor agents and i.v. antibiotics he died 11 days later as a result of thromboembolic complications resulting in multiorgan failure, confirmed by autopsy. A relation with tallimustine was thought unlikely. Tallimustine appears to be an attractive cytotoxic agent because of its unique mechanism of action, its potent preclinical anti-tumour activity in vitro and in vivo and its lack of non-haematological toxicity. However, we found no activity in patients with advanced colorectal cancer. Studies in other types of cancer are ongoing. Toxicity consisted of a highly selective neutropenia, which confirms the data obtained from phase I studies (Sessa et al., 1994; Abigerges et al., 1993; Hageboutros et al., 1994) . A concentrationdependent inhibition of human myeloid progenitor cells has been demonstrated (Volpe et al., 1993) . The striking absence of platelet toxicity as well as the low incidence of manageable non-haematological toxicities makes this agent a very attractive candidate for combination with myeloid growth factors.
